SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes - SMART

niversity Medical Center Groningen0 个研究点目标入组 98 人开始时间: 2022年6月27日最近更新: 2024年6月24日

适应症

试验速览

暂无简介。

•Age = 18 years
•Body Mass index = 27 kg/m2
•Albuminuria = 30 mg/g and = 3500 mg/g
•eGFR = 25 ml/min/1.73m2
•Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3
•months prior to enrolment
•Signed Informed Consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 78
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Diagnosis with type 1 or type 2 Diabetes
•Hba1c = 6.5% at screening
•Cardiovascular disease event in 3 months prior to enrollment
•Treatment with GLP-1 RA < 4 weeks prior to screening
•Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4 mIU/L at screening
•Acute pancreatitis < 180 days prior to screening
•History or presence of chronic pancreatitis
•Females of child-bearing potential who are pregnant, breast-feeding or have intention of
•becoming pregnant or are not using adequate contraceptive measures

发起方